Temasek (India).
The most consequential investor in Indian private markets: a ~$50bn India book (8% of the global portfolio), $10bn more committed over three years, a €5.5bn all-cash Schneider JV exit, and majority control of Manipal, now filing India's biggest healthcare IPO.
GW GP Score
Temasek's India desk operates at a scale no fund can match: >$3bn deployed and >$2bn divested in FY25 alone, with the book compounding ~35% to ~$50bn. The style spans the whole spectrum: $1bn minority in Haldiram's, majority control of Manipal (then bolting on Sahyadri at ~$700M), distressed takeover via Fullerton (Lendingkart), and monetisation at scale (Schneider JV €5.5bn cash, PB Fintech blocks of ₹3,374 Cr in two months). Ex-DBS chief Piyush Gupta arriving as India Chairman signals the next phase: heavier, more strategic, more permanent.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Manipal IPO ($1bn+, DRHP Mar 2026): India's biggest healthcare listing.
India book figure basis ($40bn firm site vs ~$50bn press): vintage mismatch.
Scale forces beta: a $50bn book cannot escape Indian market-wide drawdowns.
Computed from current dossier sources; analyst override pending.
The platform's highest score: unmatched scale in both directions, control-quality assets, and the single largest India cash exit ever recorded. Sovereign opacity and group-level policy are the only caps.
Manipal majority, Haldiram's, VFS, Lenskart: plus the listed tail
$6.4bn Schneider cash + $2bn+ FY25 divestments + systematic blocks
Consumer-premiumisation and healthcare-control theses executing at scale
>$3bn/yr in, ahead of the $10bn pledge
Deep bench + Gupta chairmanship; group restructuring noise (R)
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Manipal Health liquidity clears with credible OFS/block-sale evidence.
India book figure basis ($40bn firm site vs ~$50bn press): vintage mismatch.
Manipal IPO ($1bn+, DRHP Mar 2026): India's biggest healthcare listing.
Temasek is your comp for what patient scale earns in India, and your competition for allocations into every fund on this platform (it anchors several). Track its buy/sell mix as the institutional read on Indian valuations.
Scale forces beta: a $50bn book cannot escape Indian market-wide drawdowns.
Manipal IPO ($1bn+, DRHP Mar 2026): India's biggest healthcare listing.
Coverage initiated: inaugural GW GP Score.
Manipal IPO ($1bn+, DRHP Mar 2026): India's biggest healthcare listing.: SEBI approved Manipal Health Enterprises' IPO: ~₹8,000 Cr fresh issue plus an OFS of ~4.32 Cr shares, company now guiding to a late-July/early-August 2026 listing at a reported $10-13bn valuation. Confirms the raise-size order of magnitude in the original DRHP; no update found on Lendingkart NCLT or the group-restructuring question.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution1 positive catalyst(s), 0 pressure catalyst(s); top driver: Manipal Hospitals gets SEBI nod for a ~$1.2bn IPO.
SEBI approved a ~₹8,000 Cr fresh issue plus an OFS of ~4.32 Cr shares; Temasek's control asset now guides to a late-July/early-August 2026 listing at a reported $10-13bn valuation.
Score pressurePositive for Temasek's exit-realisation dimension once the listing prices; India's biggest-ever healthcare IPO converts a long-held control position into a monetisation engine.
Price band, listing date, and post-listing float behaviour of India's largest private hospital platform.
The funds
~$50bn India book (Mar 2025) · $10bn/3yr commitment across 1 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Balance sheet (Temasek International) | evergreen | ~$50bn India NPV | All | Via MacRitchie, Camas, V-Sciences, Sheares, Fullerton entities |
Closest booksAlteria Capital (3 shared) · Chiratae Ventures (2 shared) · India Quotient (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Vehicle cadence is neither freshly restocked nor visibly stale.
Next liquidityManipal Health · Lenskart · Rebel Foods · Cult.fit · Country Delight
3 visible exit events since Jul 2024.
Vehicle cadence is neither freshly restocked nor visibly stale.
6 up / 3 flat / 2 down tracked signals.
No senior departure flagged in key people.
6 up / 3 flat / 2 down
3 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangOla Electric · Lendingkart: names with negative 12-month mark or momentum signals in the reconstructed book.
Bought Sahyadri (~$700M, 2025); DRHP filed Mar 2026 for $1bn+ IPO: India's biggest healthcare listing
4.86% pre-IPO; sold in the Nov 2025 OFS: sixth tracked holder of this name
IPO ~2026 planned
Flat $1.45bn: final private round pre-IPO
Third tracked holder (Elevation, Z47)
Small OFS at IPO; mark well below entry
At least one cited source is dated 2026.
3 visible events tracked.
11 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · +1
Peer median 1 · +5
Peer median 66 · +25
Peer median 44 · -8
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Team data evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Team data.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
India book figure basis ($40bn firm site vs ~$50bn press): vintage mismatch.
Manipal Health: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Team data.
6 total sources · 17% primary
At least one cited source is dated 2026.
BizzBuzz: Manipal Health SEBI nod for up to $1.2bn IPO (Jul 2026)
Upgrade Team data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
Direct India book across public and private. 11 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Manipal Health | Healthcare | 2023 | Majority (~$2bn total) | Private | ▲ | Bought Sahyadri (~$700M, 2025); DRHP filed Mar 2026 for $1bn+ IPO: India's biggest healthcare listing |
| Haldiram Snacks | Consumer & Commerce | 2025 | ~10% for ~$1bn at $10bn | Private | ▲ | IHC + Alpha Wave followed |
| Lenskart | Consumer & Commerce | 2021 | Led $220M; +$200M secondary 2024 | Public | ▲ | 4.86% pre-IPO; sold in the Nov 2025 OFS: sixth tracked holder of this name |
| Rebel Foods | Consumer & Commerce | 2024 | $210M Series G led | Unicorn | ▲ | IPO ~2026 planned |
| Cult.fit | Consumer & Commerce | 2021 | ₹440 Cr to 11.88% (Mar 2026) | Unicorn | → | Flat $1.45bn: final private round pre-IPO |
| Country Delight | Consumer & Commerce | 2025 | ₹212.5 Cr: largest external holder (13.63%) | Soonicorn | ▲ | Third tracked holder (Elevation, Z47) |
| Ola Electric | EV & Climate | 2021 | Led $140M at $5.4bn (2023) | Public | ▼ | Small OFS at IPO; mark well below entry |
| Lendingkart | Fintech | 2024 | Control via Fullerton (₹252 Cr) | Acquired | ▼ | 38% → 77%, founder ousted; NCLT oppression petition Nov 2025 |
| upGrad | Consumer & Commerce | 2021 | $120M + $60M (flat $2.25bn) | Unicorn | → | — |
| VFS Global | Consumer & Commerce | 2024 | 17-18% for ~$950M | Private | ▲ | From Blackstone at $7bn EV |
| Eternal (Zomato) | Consumer & Commerce | 2023 | Camas: 2.89% (Dec 2024) | Public | → | Bought into Alibaba's sell-down |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
The FY25-26 pattern is consumer-premiumisation at scale (Haldiram's, Milky Mist, Country Delight, VFS) layered over healthcare control (Manipal/Sahyadri), with fintech distress (Lendingkart) handled by the in-house Fullerton machine rather than walked away from. >$6bn of the $10bn three-year pledge already out (R).
Dairy: premiumisation thesis (R)
Realisation · are LPs getting paid?
FY25 divestments exceeded $2bn before the Schneider close added $6.4bn of cash: the desk sells as institutionally as it buys. The forthcoming Manipal IPO converts the largest private healthcare platform in India into the next monetisation engine.
35% sold to Schneider for €5.5bn (~$6.4bn) all-cash: Temasek's largest India monetisation ever; completed Dec 18, 2025.
Two MacRitchie blocks in ~2 months: ~₹1,633 Cr + ₹1,741 Cr (Jul 3, 2026); residual ~3.8-4% locked 60 days.
Sold in the OFS as one of the named sellers.
FY24 → FY25 (R); India among top NPV contributors
The largest single India monetisation by any investor on this platform
$690M peak → ~$100M control takeover; founder litigation ongoing
Ahead of the 3-year pace (R)
Sovereign accounting discloses portfolio NPV, not deal IRRs, but the observable flow (buy $3bn, sell $2bn+, annually) is the deepest two-way book in Indian private markets. GW read: Temasek sets the clearing price for Indian growth assets; everyone else on this platform trades around it. E.
What they're doing
Minority growth as default (Shrivastav's stated focus), control where conviction demands (Manipal, Fullerton/Lendingkart).
Consumer premiumisation + healthcare + green transition + financial services as the four pillars.
Portfolio-company M&A as a compounding lever (Manipal buying Sahyadri).
Senior-statesman governance layer: Piyush Gupta as India Chairman for the relationship game.
What can break
Scale forces beta: a $50bn book cannot escape Indian market-wide drawdowns.
Lendingkart-style distress interventions carry governance and litigation overhang.
Group-level rebalancing (Singapore) can swing India allocation independent of India logic.
Manipal IPO ($1bn+, DRHP Mar 2026): India's biggest healthcare listing.
India book figure basis ($40bn firm site vs ~$50bn press): vintage mismatch.
Lendingkart NCLT oppression petition.
Group restructuring reports (2026): India-desk impact unverified.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
Temasek is your comp for what patient scale earns in India, and your competition for allocations into every fund on this platform (it anchors several). Track its buy/sell mix as the institutional read on Indian valuations.
Temasek is buyer (your exits: Schneider-style strategics aside, it takes growth positions off your books), LP (it anchors funds), and rival (it pre-empts your control deals). Map which face you're dealing with before the meeting.
The Manipal IPO will re-price Indian healthcare services wholesale; Haldiram's marks the packaged-foods premiumisation ceiling. Both are Temasek prints.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.